Retatrutide is a once-weekly synthetic peptide that activates GLP-1, GIP, and glucagon receptors; in a 2,339-participant phase 3 trial across 131 sites in 11 countries (average starting weight ~113 kg, BMI ~40) participants randomized to 4, 9, or 12 mg or placebo saw dose-dependent, large weight losses. Those on the highest dose averaged 25% weight loss at 80 weeks and 30% after a 104-week extension, and more than a third of treated participants lost at least 30% of body weight. The trial also reported substantial secondary benefits: knee pain fell by up to 62% among participants with osteoarthritis, obstructive sleep apnea events per hour fell by up to 57%, and cardiometabolic markers improved (blood pressure, triglycerides, LDL); among participants with prediabetes, resolution occurred in over 90%.
The molecule mimics three hormones with complementary effects on appetite, insulin, lipid metabolism and gastric emptying, and is stabilized for a six-day half-life to allow weekly dosing. Safety signals matched those of current GLP-1/GIP drugs - mostly transient gastrointestinal side effects - plus dizziness and low blood pressure in some, and small numbers of cardiovascular events and pancreatitis that the trial was not powered to evaluate for rare risks. Key limitations include the absence of an active comparator (for example, tirzepatide) and the need for larger, longer studies to define long-term safety and comparative effectiveness.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.